| | A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-mycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of M . . . |
Completed |
30 Mar 2023 |
| | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Intranasal INNA-051 for Prevention of COVID-19 in Adults Following Close Contact . . . |
Terminated |
13 May 2022 |
| | A Phase 2, Randomized, Double-blind, Placebo-controlled, Double-dummy, Multicenter Trial Assessing the Efficacy and Safety of Two Dose Regimens of JNJ-64281802 for the Prevention of Dengue Infection . . . |
Pending |
30 Nov -0001 |
| | A Phase 2, Randomized, Double-dummy, Observer-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Compared to Pfizer-BioNTech COVID-19 Vaccine in Healthy Seronegativ . . . |
Pending |
30 Nov -0001 |
| | A Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vaccine . . . |
Completed |
19 Jul 2022 |
| | A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) with Matrix-M™ Adjuvant in Children 6 months to < 1 . . . |
Pending |
15 Mar 2023 |
| | A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) . . . |
Ongoing |
27 Apr 2023 |
| | A Phase 2/3 Study of S-217622 in Participants Infected with SARS-CoV-2 |
Terminated |
02 May 2022 |
| | A Phase 2a Open-Label Study in Infants with REspiratory Syncytial VIRus Lower RespirAtory Tract Infection, Followed by a DoubLe-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability, Ph . . . |
Terminated |
13 Oct 2021 |
| | A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults with Different Rabies Exposure Risks . . . |
Completed |
21 Sep 2022 |
| | A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmo . . . |
Ongoing |
27 Jul 2022 |
| | A Phase 3 Clinical Trial to Study Short Duration Versus Standard Response-Guided Therapy with MK-3034 (SCH 503034)/Boceprevir Combined with PegIntron and Ribavirin in Previously Untreated Non- Cirrhot . . . |
Completed |
28 Dec 2021 |
| | A Phase 3 Multi-Center International, Randomized, Active-Controlled Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost with UB-612 Vaccine . . . |
Ongoing |
28 Nov 2022 |
| | A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cance . . . |
Ongoing |
18 Jan 2023 |
| | A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis . . . |
Ongoing |
26 Apr 2023 |
| | A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia . . . |
Completed |
14 Oct 2019 |
| | A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia . . . |
Completed |
14 Oct 2019 |
| | A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients . . . |
Pending |
30 Nov -0001 |
| | A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or rela . . . |
Ongoing |
28 Apr 2023 |
| | A Phase 3 Randomized, Double-blind Study of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel for the First-line Treatment of Patients with Her2-positive Metastatic Breast Cancer . . . |
Completed |
05 Aug 2020 |
| | A Phase 3 Randomized, Double-blind Study of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel for the First-line Treatment of Patients with Her2-positive Metastatic Breast Cancer . . . |
Completed |
05 Aug 2020 |
| | A Phase 3 Randomized, Double-Blind, Active-Controlled, Multicenter Study of the Long-Term Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects with Osteoarthritis of the Hip or . . . |
Completed |
17 Jul 2019 |
| | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and N . . . |
Ongoing |
12 Apr 2021 |
| | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with Active Lupus Nephritis . . . |
Pending |
24 Mar 2023 |
| | A Phase 3 Randomized, Double-blinded, Active-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Fabagal® (agalsidase beta) in Patients with Fabry Disease . . . |
Pending |
03 May 2023 |